Lack of association of OPRM1 genotype and smoking cessation.
- Authors
- MunafΓ², Marcus R; Johnstone, Elaine C; Aveyard, Paul; Marteau, Theresa
- Year
- 2013
- Journal
- Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
- PMID
- 22990223
- DOI
- 10.1093/ntr/nts174
INTRODUCTION: Previous studies have reported an association between ΞΌ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism in the OPRM1 gene is associated with cessation and whether this variant moderates the effects of higher doses of NRT on abstinence. METHODS: Participants were recruited from the practices of primary care physicians in the United Kingdom. Patients smoking an average of at least 10 cigarettes a day, who wanted to quit and were 18 years or older were eligible for inclusion. A total of N = 633 participants were recruited into the original trial, of whom complete data for pharmacogenetic analyses were available on n = 598. Logistic regression was used to test for the effects of OPRM1 genotype and NRT dose, including the genotype Γ dose interaction term, on smoking status at 4-week, and 26-week follow-up. Analyses were adjusted for potential confounders. RESULTS: There was no evidence of a genotype effect at either follow-up, and no evidence of a genotype Γ dose interaction effect. CONCLUSIONS: OPRM1 genotype may not affect the likelihood of smoking cessation, and it may not influence response to high- versus low-dose NRT. OPRM1 may have at most only a modest role in explaining cigarette smoking and cessation.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | β | 2023 | β |
| Significant association of mu-opioid receptor 1 haplotype with tobacco smoking in healthy control subjects but not in patients with schizophrenia and alcohol dependence. | Konjevod M et al. | β | 2020 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Endogenous opioid system: a promising target for future smoking cessation medications. | Norman H et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions. | Yang J et al. | β | 2016 | β |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | β | 2015 | β |
| Association between Opioid Receptor mu 1 (OPRM1) Gene Polymorphisms and Tobacco and Alcohol Consumption in a Spanish Population. | FrancΓ¨s F et al. | β | 2015 | β |
| New mechanisms and perspectives in nicotine withdrawal. | Jackson KJ et al. | β | 2015 | β |
| Endogenous opiates and behavior: 2013. | Bodnar RJ | β | 2014 | β |
| Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. | Leventhal AM et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |